Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Control of Metastases via Myeloid CD39 and NK Cell Effector Function
Juming Yan, Xian-Yang Li, Amelia Roman Aguilera, et al.
Cancer Immunology Research (2020) Vol. 8, Iss. 3, pp. 356-367
Open Access | Times Cited: 68

Showing 1-25 of 68 citing articles:

The adenosine pathway in immuno-oncology
Bertrand Allard, David Allard, Laurence Buisseret, et al.
Nature Reviews Clinical Oncology (2020) Vol. 17, Iss. 10, pp. 611-629
Closed Access | Times Cited: 398
Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response
Dongrui Wang, Xianlin Wu, Yingli Sun
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 290
Targeting CD39 in cancer
Achim K. Moesta, Xian-Yang Li, Mark J. Smyth
Nature reviews. Immunology (2020) Vol. 20, Iss. 12, pp. 739-755
Closed Access | Times Cited: 251
ATP and cancer immunosurveillance
Oliver Kepp, Lucillia Bezu, Takahiro Yamazaki, et al.
The EMBO Journal (2021) Vol. 40, Iss. 13
Open Access | Times Cited: 158
CD39/CD73/A2AR pathway and cancer immunotherapy
Chenglai Xia, Shuanghong Yin, Kenneth K.W. To, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 143
CD39 Regulation and Functions in T Cells
Eleonora Timperi, Vincenzo Barnaba
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 15, pp. 8068-8068
Open Access | Times Cited: 115
P2X7 in Cancer: From Molecular Mechanisms to Therapeutics
Romain Lara, Elena Adinolfi, Catherine Α. Harwood, et al.
Frontiers in Pharmacology (2020) Vol. 11
Open Access | Times Cited: 136
Targeting CD73 to augment cancer immunotherapy
Meejeon Roh, Derek A. Wainwright, Jennifer D. Wu, et al.
Current Opinion in Pharmacology (2020) Vol. 53, pp. 66-76
Open Access | Times Cited: 117
CD39+PD-1+CD8+ T cells mediate metastatic dormancy in breast cancer
Paulino Tallón de Lara, Héctor Castañón, Marijne Vermeer, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 64
Adenosine-Metabolizing Enzymes, Adenosine Kinase and Adenosine Deaminase, in Cancer
Г. А. Жулай, Е. К. Олейник, Mikhail A. Shibaev, et al.
Biomolecules (2022) Vol. 12, Iss. 3, pp. 418-418
Open Access | Times Cited: 63
CD73 Inhibits cGAS–STING and Cooperates with CD39 to Promote Pancreatic Cancer
Célia Jacoberger-Foissac, Isabelle Cousineau, Yacine Barèche, et al.
Cancer Immunology Research (2022) Vol. 11, Iss. 1, pp. 56-71
Open Access | Times Cited: 42
Review immune response of targeting CD39 in cancer
Yao Liu, Zhongliang Li, Xiaoguang Zhao, et al.
Biomarker Research (2023) Vol. 11, Iss. 1
Open Access | Times Cited: 24
Combined Blockade of TIGIT and CD39 or A2AR Enhances NK-92 Cell-Mediated Cytotoxicity in AML
Franziska Brauneck, Elisa Seubert, Jasmin Wellbrock, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 23, pp. 12919-12919
Open Access | Times Cited: 43
Inflammasomes in Cancer Progression and Anti-Tumor Immunity
Sebastian Lillo, Maya Saleh
Frontiers in Cell and Developmental Biology (2022) Vol. 10
Open Access | Times Cited: 35
CD39 – A bright target for cancer immunotherapy
Shuwei Guo, Fengfeng Han, Wei Zhu
Biomedicine & Pharmacotherapy (2022) Vol. 151, pp. 113066-113066
Open Access | Times Cited: 35
Metabolic crosstalk: Extracellular ATP and the tumor microenvironment in cancer progression and therapy
Sourav Shukla, Parameswar Dalai, Reena Agrawal-Rajput
Cellular Signalling (2024) Vol. 121, pp. 111281-111281
Closed Access | Times Cited: 6
Fully human anti-CD39 antibody potently inhibits ATPase activity in cancer cells via uncompetitive allosteric mechanism
Bradley N. Spatola, Alana G. Lerner, Clifford Wong, et al.
mAbs (2020) Vol. 12, Iss. 1
Open Access | Times Cited: 33
Targeting inflamed and non-inflamed melanomas: biological background and clinical challenges
Alice Indini, Daniela Massi, Matteo Pirro, et al.
Seminars in Cancer Biology (2022) Vol. 86, pp. 477-490
Open Access | Times Cited: 20
Tumor intrinsic and extrinsic functions of CD73 and the adenosine pathway in lung cancer
Ryan R. Kowash, Esra A. Akbay
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 12
Targeting Immunosuppressive Adenosine Signaling: A Review of Potential Immunotherapy Combination Strategies
David J. Zahavi, James W. Hodge
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 10, pp. 8871-8871
Open Access | Times Cited: 12
NMDAR antagonists suppress tumor progression by regulating tumor-associated macrophages
Dongchen Yuan, Jing Hu, Xiaoman Ju, et al.
Proceedings of the National Academy of Sciences (2023) Vol. 120, Iss. 47
Open Access | Times Cited: 12
Nanoparticles targeting the adenosine pathway for cancer immunotherapy
Kehua Jiang, Jian Wu, Qing Wang, et al.
Journal of Materials Chemistry B (2024) Vol. 12, Iss. 24, pp. 5787-5811
Closed Access | Times Cited: 4
CAR-CIK vs. CAR-T: benchmarking novel cytokine-induced killer cells as solid tumor immunotherapy in ErbB2+ rhabdomyosarcoma
Laura M. Moser, Catrin Heim, Sebastian E. Koschade, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
The CD39/CD73/Adenosine and NAD/CD38/CD203a/CD73 Axis in Cutaneous T-Cell Lymphomas
Liang Lin, Gabriele Roccuzzo, Yuliya Yakymiv, et al.
Cells (2025) Vol. 14, Iss. 4, pp. 309-309
Open Access
Ectonucleotidases
Raíssa Leite-Aguiar, Marco De Giorgi, Luiz Eduardo Baggio Savio, et al.
Elsevier eBooks (2025)
Closed Access
Page 1 - Next Page

Scroll to top